Appili Therapeutics Inc.
APLIF
$0.01
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.92% | -32.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.13% | -34.03% | |||
| Operating Income | 18.64% | 34.36% | |||
| Income Before Tax | 21.36% | -594.33% | |||
| Income Tax Expenses | 13.90% | 15.54% | |||
| Earnings from Continuing Operations | 20.49% | -668.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.49% | -668.41% | |||
| EBIT | 18.64% | 34.36% | |||
| EBITDA | 18.66% | 34.43% | |||
| EPS Basic | 20.27% | -669.23% | |||
| Normalized Basic EPS | 20.00% | -600.00% | |||
| EPS Diluted | 20.27% | -669.23% | |||
| Normalized Diluted EPS | 20.00% | -600.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||